138 completed, 38 terminated, 25 unknown, 21 recruiting. 111 Phase 2, 88 Phase 1, 27 Not applicable, 15 Phase 3, 5 Early Phase 1.
Follow Malignant Melanoma: new trials by email Literature Review of Malignant Melanoma trials Research Report on Malignant Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons PRISMA-interventions - Cancer, Lung Cancer | Not applicable | Recruiting | University of Regensburg | 384 | 2026-04-21 | 2026-08-26 |
| An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 266 | 2025-12-03 | 2026-01-28 |
| Reducing Symptom Burden Through Physical Exercise in Melanoma Patients Supervised 12-week Resistance and Endurance Exercise Program - Malignant Melanoma | Not applicable | Recruiting | Universität Duisburg-Essen | 86 | 2025-08-18 | 2026-07-08 |
| Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy Baseline 89-Zr Pembrolizumab Immuno PET-CT, Proteomic assay, Follow-up 89-Zr Pembrolizumab Immuno PET-CT - Triple Negative Breast Cancer, Uterine Cervical Cancer | Phase 2 | Not yet recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 60 | 2025-06-01 | 2025-05-16 |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) Intismeran autogene, Pembrolizumab, Placebo - Malignant Melanoma | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2025-05-29 | 2026-09-28 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Video-Tumorboard PLUS Malignant Melanoma, Telemedicine | Recruiting | University Hospital Muenster | 300 | 2025-05-01 | 2025-05-20 | |
| A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors PF-08046031 - Malignant Melanoma, Melanoma | Phase 1 | Terminated | Pfizer | 11 | 2025-05-01 | 2026-03-18 |
| Preoperative Planning With PSMA-PET in Melanoma Surgery Trial 68Ga-PSMA - Malignant Melanoma | Phase 2 | Recruiting | Royal Marsden NHS Foundation Trust | 16 | 2025-03-11 | 2025-07-01 |
| A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma Temozolomide、Fruquintinib、Cadonilimab - Malignant Melanoma | Not applicable | Not yet recruiting | Fudan University | 28 | 2024-09-01 | 2024-08-14 |
| T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma T3011 + Cobimetinib - Melanoma, Malignant Melanoma | Phase 2 | Suspended | ImmVira Pharma Co. Ltd | 68 | 2024-06-30 | 2024-02-01 |
| Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab - Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC) | Phase 1 | Recruiting | LG Chem | 76 | 2024-06-05 | 2025-11-24 |
| IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma Pembrolizumab, Nivolumab, Ipilimumab/Nivolumab - Metastatic Melanoma, Malignant Melanoma | Not applicable | Completed | Institute of Oncology Ljubljana | 132 | 2024-03-31 | 2026-03-02 |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies CTX-8371 - Non Small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1 | Recruiting | Compass Therapeutics | 85 | 2024-03-19 | 2026-07-28 |
| GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) - Head and Neck Cancer, Malignant Melanoma | Phase 1 / Phase 2 | Recruiting | GeneMedicine Co., Ltd. | 125 | 2024-02-20 | 2024-03-21 |
| Improved Early Diagnosis in Female Pelvic Cancer With OC Detect Ovarian Cancer, Endometrial Cancer | Completed | Region Skane | 490 | 2024-02-01 | 2025-04-18 | |
| AMT-253 in Patients With Advanced Solid Tumours AMT-253 for injection - Malignant Melanoma, Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Multitude Therapeutics Inc. | 96 | 2024-01-31 | 2025-09-05 |
| FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis Faecal Microbiota Transplantation (FMT), Placebo - Diarrhea, Colitis | Not applicable | Recruiting | University of Aarhus | 20 | 2024-01-23 | 2025-11-17 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
Showing 20 of 241. Sign in to see all of them.
Melanoma (241) · Carcinoma, Non-Small-Cell Lung (19) · Neoplasms (17) · Skin Neoplasms (11) · Carcinoma, Renal Cell (10) · Neoplasm Metastasis (10) · Squamous Cell Carcinoma of Head and Neck (9) · Breast Neoplasms (8) · Colorectal Neoplasms (7) · Brain Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Head and Neck Neoplasms (4) · Lung Neoplasms (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Uterine Cervical Neoplasms (4)
Neoplasms by Histologic Type (241) · Neoplasms by Site (241) · Neoplasms, Germ Cell and Embryonal (241) · Neoplasms, Nerve Tissue (241) · Neuroectodermal Tumors (241) · Neuroendocrine Tumors (241) · Nevi and Melanomas (241) · Skin Diseases (241) · Skin and Connective Tissue Diseases (241) · Skin Neoplasms (230) · Neoplasms (224) · Neoplasms, Glandular and Epithelial (29) · Carcinoma (25) · Pathological Conditions, Signs and Symptoms (22) · Urogenital Diseases (21)
pembrolizumab (23) · Ipilimumab (15) · Vemurafenib (15) · Nivolumab (11) · Dacarbazine (10) · cobimetinib (8) · Cyclophosphamide (7) · Granulocyte-Macrophage Colony-Stimulating Factor (6) · Interleukin-2 (6) · Temozolomide (6) · atezolizumab (6) · dabrafenib (6) · aldesleukin (5) · binimetinib (5) · trametinib (5)
Hoffmann-La Roche (22) · Bristol-Myers Squibb (6) · University Hospital Tuebingen (6) · Merck Sharp & Dohme LLC (5) · Celgene (4) · Inge Marie Svane (4) · Pfizer (4) · Cytos Biotechnology AG (3) · Genentech, Inc. (3) · Hadassah Medical Organization (3) · Immunocore Ltd (3) · Institute of Oncology Ljubljana (3) · Ludwig Institute for Cancer Research (3) · National Cancer Institute (NCI) (3) · Oslo University Hospital (3)
United States (109) · Germany (35) · United Kingdom (30) · Italy (27) · France (26) · Australia (24) · Sweden (20) · Israel (18) · Canada (17) · Denmark (15) · Spain (15) · Switzerland (15) · China (12) · Netherlands (11) · Belgium (10)
Dirk Schadendorf, Prof. Dr. (4) · Claus Garbe, Prof. Dr. (2) · Daniel Fowler, M.D. (2) · Evan Hersh, MD (2) · F. Stephen Hodi, MD (2) · Adil Daud, M.D. (1) · Adil Daud, MD (1) · Agop Bedikian, MD (1)
PMID 24983357, PMID 22256804, PMID 32746839, PMID 23457002, PMID 36310331, PMID 36648215, PMID 16710345, PMID 16947019, PMID 18334033, PMID 18452610, PMID 18566444, PMID 19609242, PMID 20030854, PMID 20564083, PMID 20818844, PMID 21030496, PMID 21262599, PMID 21456091, PMID 21639808, PMID 21917625, PMID 22165955, PMID 22202581, PMID 22356324, PMID 22555974, PMID 22575589, PMID 22651703, PMID 23288588, PMID 23295794, PMID 23402397, PMID 23502769, PMID 23650429, PMID 23724867, PMID 24136099, PMID 24145345, PMID 24508103, PMID 24577748, PMID 24582505, PMID 25037139, PMID 25265494, PMID 25304729, PMID 25505948, PMID 25667295, PMID 25884515, PMID 25980594, PMID 26206146, PMID 26460303, PMID 26771550, PMID 27087489, PMID 27480103, PMID 27571185
2014 (2), 2018 (2), 2004 (1), 2005 (1), 2009 (1), 2016 (1), 2019 (1), 2023 (1), 2025 (1), U10CA021115 (1)